SCH was associated with the risk of the composite event in patients with a diagnosis other than MI/ST-segment elevation MI (STEMI), prior PCI, single-vessel coronary artery diseases (CAD), total stent length (TSL) <38 mm, second-generation drug-eluting stent (DES) implantation, diabetes mellitus, body mass index (BMI) ≥25 kg/m2, highly sensitive C-reactive protein (hsCRP) ≥1.0 mg/l and low-density lipoprotein (LDL) reduction <26 mg/dl (Fig. 1). The gene discussed is CRP; the disease is coronary artery disorder.